AR and breast carcinoma: Renewed focus on AR in breast cancer has shown that alterations in the antagonist relationship between ERα and AR may play a role in the development of breast cancer, and in particular, skewed AR ERα expression ratio may be a factor that influences the development of resistance to ERα -directed therapy (8–10).